Torthaí cuardaigh - Torben Rixecker

  • 1 - 2 toradh as 2 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL

    Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL de réir Niels Murawski, Michael Pfreundschuh, Samira Zeynalova, Viola Poeschel, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Christian Schmidt, Michael Hallek, Mathias Witzens‐Harig, Lorenz Trümper, Torben Rixecker, C. Zwick

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study

    TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study de réir Sina A. Tegethoff, Guy Danziger, Dennis Kühn, Charlotte Kimmer, Thomas Adams, Lena Heintz, Carlos Metz, Katharina Reifenrath, Rebecca Angresius, Sebastian Mang, Torben Rixecker, André Becker, Jürgen Geisel, Christophe Jentgen, Frederik Seiler, Matthias Reichert, Franziska Fröhlich, Sascha Meyer, Jürgen Rissland, Sebastian Ewen, Gudrun Wagenpfeil, Katharina Last, Sigrun Smola, Robert Bals, Frank Lammert, Sören L. Becker, Marcin Krawczyk, Philipp M. Lepper, Cihan Papan

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: